title: Evaluation of the in vivo mutagenicity of isopropyl methanesulfonate in acute and 28-day studies.
abstract: Understanding the mutagenic dose response could prove beneficial in the management of pharmaceutically relevant impurities. For most alkyl ester impurities, such as isopropyl methanesulfonate (IPMS), little in vivo mutagenicity data exist for dose analysis. The likelihood of a sublinear dose response for IPMS was assessed by comparing the Swain Scott constant, the SN 1/SN 2 reaction mechanism and the O(6) :N(7) guanine adduct ratio to that of more well-known alkyl esters. Based on available information, IPMS was predicted to have a mutagenic profile most like ethyl nitrosourea. To test this hypothesis, mature male Wistar Han rats were administered IPMS using acute (single administration at 3.5 to 56 mg/kg) or subchronic (28 days at 0.125 to 2 mg/kg/day) exposures. The in vivo Pig-a mutation assay was used to identify mutant phenotype reticulocyte (Ret) and red blood cell (RBC) populations. The maximum mutant response occurred approximately 15 and 28 days after the last dose administration in the mutant Ret and RBC populations respectively in the acute study and on Day 29 and 56 in the mutant Ret and RBC populations, respectively, in the subchronic study. A comparison of RBC mutant frequencies from acute and subchronic protocols suggests a sublinear response; however, this was not substantiated by statistical analysis. A No Observed Effect Level (NOEL) of 0.25 mg/kg/day resulted in a Permitted Daily Exposure equivalent to the Threshold of Toxicological Concern. An estimate of the NOEL based on the previously mentioned factors, in practice, would have pre-empted further investigation of the potent mutagen IPMS.
authors.affiliation: Pfizer Worldwide Research and Development, Genetic Toxicology, Groton, Connecticut.
authors.forename: Stephanie L
authors.initials: SL
authors.lastname: Coffing
authors.forename: Michelle O
authors.initials: MO
authors.lastname: Kenyon
authors.forename: Joel I
authors.initials: JI
authors.lastname: Ackerman
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Shutsky
authors.forename: Krista L
authors.initials: KL
authors.lastname: Dobo
mesh_terms: D000818:Animals; D018957:CD59 Antigens / Q000032:analysis; D004912:Erythrocytes / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008565:Membrane Proteins / Q000235:genetics*; D008698:Mesylates / Q000008:administration & dosage / Q000633:toxicity*; D015162:Micronucleus Tests; D009152:Mutagenicity Tests / Q000379:methods; D009153:Mutagens / Q000008:administration & dosage / Q000633:toxicity*; D019055:No-Observed-Adverse-Effect Level; D051381:Rats; D017208:Rats, Wistar; D012156:Reticulocytes / Q000187:drug effects* / Q000378:metabolism
chemical_list: D018957:CD59 Antigens; D008565:Membrane Proteins; D008698:Mesylates; D009153:Mutagens; C080086:phosphatidylinositol glycan-class A protein; C002531:isopropylmethanesulfonate
keywords: In vivo mutation assay; Pig-a mutation assay; alkylating agent; impurities; in vivo genotoxicity